IN2014MN00357A - - Google Patents

Info

Publication number
IN2014MN00357A
IN2014MN00357A IN357MUN2014A IN2014MN00357A IN 2014MN00357 A IN2014MN00357 A IN 2014MN00357A IN 357MUN2014 A IN357MUN2014 A IN 357MUN2014A IN 2014MN00357 A IN2014MN00357 A IN 2014MN00357A
Authority
IN
India
Prior art keywords
hydrophobic
peptides
peptide
yrfli
irfli
Prior art date
Application number
Other languages
English (en)
Inventor
Michael John Gait
Andrey Alexandrovich Arzumanov
Amer F Saleh
Matthew J A Wood
Corinne Betts
Taeyoung Koo
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1115014.1A external-priority patent/GB201115014D0/en
Priority claimed from GBGB1211740.4A external-priority patent/GB201211740D0/en
Application filed by Medical Res Council filed Critical Medical Res Council
Publication of IN2014MN00357A publication Critical patent/IN2014MN00357A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003Peptide-nucleic acids (PNAs)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
IN357MUN2014 2011-08-30 2012-08-29 IN2014MN00357A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161528804P 2011-08-30 2011-08-30
GBGB1115014.1A GB201115014D0 (en) 2011-08-30 2011-08-30 Peptides
GBGB1211740.4A GB201211740D0 (en) 2012-07-03 2012-07-03 Peptides
PCT/GB2012/052116 WO2013030569A2 (en) 2011-08-30 2012-08-29 Peptides

Publications (1)

Publication Number Publication Date
IN2014MN00357A true IN2014MN00357A (es) 2015-06-19

Family

ID=47756980

Family Applications (1)

Application Number Title Priority Date Filing Date
IN357MUN2014 IN2014MN00357A (es) 2011-08-30 2012-08-29

Country Status (10)

Country Link
US (1) US9302014B2 (es)
EP (1) EP2751128B1 (es)
JP (1) JP6077543B2 (es)
CN (1) CN103998458B (es)
AU (1) AU2012300633B2 (es)
BR (1) BR112014004902B1 (es)
CA (1) CA2846218C (es)
ES (1) ES2876939T3 (es)
IN (1) IN2014MN00357A (es)
WO (1) WO2013030569A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016016153A2 (pt) 2014-01-13 2017-12-12 Berg Llc composições de enolase 1 (eno1) e usos das mesmas
WO2015188020A1 (en) * 2014-06-06 2015-12-10 Vivoscript, Inc. Methods for repairing cartilage damage
CN111388680B (zh) * 2015-01-28 2024-01-05 中国科学院天津工业生物技术研究所 一种多肽复合物作为多肽或蛋白质药物载体的应用、方法及其融合蛋白复合物
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
EP3399993B1 (en) * 2016-01-06 2021-03-31 D. Travis Wilson Methods for the treatment of duchenne muscular dystrophy
CN109477109B (zh) 2016-04-29 2022-09-23 萨勒普塔医疗公司 靶向人lmna的寡核苷酸类似物
CN109563144B (zh) 2016-06-01 2023-03-28 雅斯娜 化合物
IL301091A (en) 2016-07-05 2023-05-01 Biomarin Tech Bv Oligonucleotides containing a bicyclic skeleton and their use for the treatment of genetic diseases
US20200131231A1 (en) * 2017-02-17 2020-04-30 Oxford University Innovation Limited Cell penetrating peptides
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
TW201919682A (zh) 2017-08-08 2019-06-01 西班牙商阿爾米雷爾有限公司 活化Nrf2路徑的新穎化合物
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
CN108070025B (zh) * 2017-10-24 2019-11-19 中山大学附属口腔医院 一种细胞穿透肽和细胞穿透肽复合物及二者的应用
JP2021521794A (ja) * 2018-04-26 2021-08-30 サレプタ セラピューティクス, インコーポレイテッド 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート
US11559586B2 (en) * 2018-05-22 2023-01-24 Children's Medical Center Corporation Nanoparticles for treatment of choroidal neovascularization and other indications
GB201812980D0 (en) * 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812972D0 (en) * 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
BR112021010982A2 (pt) 2018-12-07 2021-08-31 Oxford University Innovation Limited Ligantes
WO2020158792A1 (ja) * 2019-01-30 2020-08-06 国立研究開発法人国立精神・神経医療研究センター 核酸送達複合体
GB201911403D0 (en) * 2019-08-09 2019-09-25 Univ Oxford Innovation Ltd Conjugate and uses thereof
EP4370677A1 (en) 2021-07-16 2024-05-22 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Oligonucleotide for inhibiting quaking activity
JPWO2023026994A1 (es) 2021-08-21 2023-03-02
WO2023214373A2 (en) 2022-05-06 2023-11-09 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Oligonucleotide
GB202216207D0 (en) * 2022-11-01 2022-12-14 Univ Oxford Innovation Ltd Shortened cell-penetrating peptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE419273T1 (de) 1998-11-13 2009-01-15 Cyclacel Ltd Translokationsvektoren abgeleitet von der antennapedia homeodomain helix 3
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
JP5864100B2 (ja) 2007-06-29 2016-02-17 サレプタ セラピューティクス インコーポレイテッド 組織特異的ペプチドコンジュゲートおよび方法
US20110130346A1 (en) 2008-05-30 2011-06-02 Isis Innovation Limited Peptide conjugates for delvery of biologically active compounds
US8575305B2 (en) * 2008-06-04 2013-11-05 Medical Research Council Cell penetrating peptides
US20120309684A1 (en) 2009-11-30 2012-12-06 Isis Innovation Limited Conjugates for delivery of biologically active compounds

Also Published As

Publication number Publication date
US9302014B2 (en) 2016-04-05
CA2846218A1 (en) 2013-03-07
EP2751128A2 (en) 2014-07-09
WO2013030569A3 (en) 2013-06-13
EP2751128B1 (en) 2021-03-03
BR112014004902A2 (pt) 2017-07-04
AU2012300633A8 (en) 2014-05-29
AU2012300633A1 (en) 2014-03-06
CA2846218C (en) 2020-09-01
CN103998458A (zh) 2014-08-20
US20140342992A1 (en) 2014-11-20
BR112014004902B1 (pt) 2022-02-08
JP6077543B2 (ja) 2017-02-08
AU2012300633B2 (en) 2017-04-27
CN103998458B (zh) 2018-10-09
ES2876939T3 (es) 2021-11-15
JP2014526238A (ja) 2014-10-06
WO2013030569A2 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
IN2014MN00357A (es)
EP2579899B1 (en) Cell-penetrating peptides and uses thereof
BRPI0816405B8 (pt) complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação
MX2014008468A (es) Complementacion funcional bipartita inducida por antigenos, dual.
MX344219B (es) Productos farmaceuticos peptidicos mejorados para resistencia a insulina.
MX2018013981A (es) Productos farmaceuticos peptidicos mejorados para la resistencia a la insulina.
SG10201811729PA (en) Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
EP4286400A3 (en) Improved peptide pharmaceuticals
EP2570430A3 (en) Peptide vaccines with Seq ID No: 78, 41, 44, 46 or 48 for cancers expressing tumor-associated antigens
WO2012012352A3 (en) Modified peptides and proteins
JP2014224126A5 (es)
NZ629394A (en) Synthetic brassica-derived chloroplast transit peptides
Kawaguchi et al. Identification of cellular proteins interacting with octaarginine (R8) cell-penetrating peptide by photo-crosslinking
WO2014134509A3 (en) Peptide-and amine-modified glucan particles for delivery of therapeutic cargoes
MX2009007261A (es) Vacuna de peptido foxp3.
WO2011135222A3 (fr) Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles
WO2011048503A3 (en) Peptides that bind the alpha-fetoprotein (afp) receptor and uses thereof
IN2014DN09963A (es)
MX2010005816A (es) Epítopos de péptido de stat3.
MX2015005867A (es) Moleculas de transporte especificas de proteoglicano c4s.
MY151307A (en) Peptides having antimicrobial activity
NZ603379A (en) Ect2 peptides and vaccines including the same
JP2011512364A5 (es)
WO2013162948A3 (en) Fluorous peptide microarray, detection process using a fluorous peptide microarray, and process of forming a fluorous peptide microarray
WO2012116210A3 (en) Peptide for the induction of immune tolerance as treatment for systemic lupus erythematosus